Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi to pay $2.9B for Proven­tion Bio and its di­a­betes-de­lay­ing drug Tzield

Sanofi and Proven­tion Bio have made a $2.9 bil­lion deal for the French drug­mak­er to ac­quire the biotech, which last year won ap­proval for its drug to de­lay the on­set of type 1 di­a­betes.

Sanofi will pay $25 a share, the com­pa­nies an­nounced in a press re­lease, a 273% pre­mi­um over the New Jer­sey-based biotech’s clos­ing price Fri­day. The com­pa­nies al­ready had a deal for Sanofi to co-pro­mote the drug in the US, which they struck in Oc­to­ber, that gave Sanofi first dibs on ne­go­ti­at­ing any li­cens­ing rights for the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA